Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2220 in Transthyretin Amyloid Cardiomyopathy (DepleTTR-CM)
NCT06183931Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloid cardiomyopathy (ATTR-CM) comparing ALXN2220 with Placebo (2 arms). Primary endpoint: Total Occurrence of All-Cause Mortality and Cardiovascular Clinical Events at Month 48. Started Jan 2024; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06183931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183931.